{"id":658644,"date":"2023-07-07T07:36:01","date_gmt":"2023-07-07T07:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=658644"},"modified":"2023-07-07T07:36:01","modified_gmt":"2023-07-07T07:36:01","slug":"craniopharyngioma-pipeline-clinical-trials-and-companies-novartis-blaze-bioscience-bristol-myers-squibb-insys-therapeutics-zafgen","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/craniopharyngioma-pipeline-clinical-trials-and-companies-novartis-blaze-bioscience-bristol-myers-squibb-insys-therapeutics-zafgen_658644.html","title":{"rendered":"Craniopharyngioma Pipeline, Clinical Trials, and Companies &#8211; Novartis, Blaze Bioscience, Bristol Myers Squibb, INSYS Therapeutics, Zafgen"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Craniopharyngioma Pipeline, Clinical Trials, and Companies - Novartis, Blaze Bioscience, Bristol Myers Squibb, INSYS Therapeutics, Zafgen \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Craniopharyngioma Pipeline, Clinical Trials, and Companies - Novartis, Blaze Bioscience, Bristol Myers Squibb, INSYS Therapeutics, Zafgen \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s Craniopharyngioma Pipeline Insight, 2023&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Craniopharyngioma market. A detailed picture of the Craniopharyngioma pipeline landscape is provided, which includes the disease overview and Craniopharyngioma treatment guidelines.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/craniopharyngioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dprr\">Craniopharyngioma Pipeline Insight, 2023<\/a><\/strong>&#8221; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Craniopharyngioma market. A detailed picture of the Craniopharyngioma pipeline landscape is provided, which includes the disease overview and Craniopharyngioma treatment guidelines.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/craniopharyngioma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dprr\">Key Takeaways from the Craniopharyngioma Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leading Craniopharyngioma companies developing novel drug candidates to improve the Craniopharyngioma treatment landscape include Novartis, Blaze Bioscience, Bristol Myers Squibb, INSYS Therapeutics, Zafgen, and many others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Promising Craniopharyngioma pipeline therapies in various stages of development include Nivolumab,&nbsp; DAY101, &nbsp;ZGN-440, Trametinib, and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Craniopharyngioma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Craniopharyngioma is a rare type of noncancerous (benign) brain tumor. Craniopharyngioma begins near the brain&#8217;s pituitary gland, which secretes hormones that control many body functions. As a craniopharyngioma slowly grows, it can affect the function of the pituitary gland and other nearby structures in the brain. Craniopharyngioma can occur at any age, but it occurs most often in children and older adults. Symptoms include gradual changes in vision, fatigue, excessive urination, and headaches. Children with craniopharyngioma may grow slowly and may be smaller than expected<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/d91712e095164c6a612701db04eb850a.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Discover more about the Craniopharyngioma @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/craniopharyngioma-pipeline-insightt?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Craniopharyngioma Disease Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Craniopharyngioma Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis: Nivolumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Blaze Biosciences: DAY101<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bristol Myers Squibb: ZGN-440<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Zafgen: Trametinib<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/craniopharyngioma-pipeline-insightt?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Scope of the Craniopharyngioma Pipeline Report&nbsp;<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage:&nbsp;Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Craniopharyngioma Companies: Novartis, Blaze Therapeutics, Bristol Myers Squibb, Zafgen, and many others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Key Craniopharyngioma Pipeline Therapies: Nivolumab, DAY101, ZGN-440, Trametinib, and many others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Find out more about the Craniopharyngioma treatment options in development@ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/craniopharyngioma-pipeline-insightt?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Craniopharyngioma Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Craniopharyngioma Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Craniopharyngioma Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Craniopharyngioma Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Craniopharyngioma Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Craniopharyngioma Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Craniopharyngioma Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Craniopharyngioma Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Craniopharyngioma Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Craniopharyngioma Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Craniopharyngioma Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Craniopharyngioma Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. CraniopharyngiomaCollaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Craniopharyngioma Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Craniopharyngioma Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">About&nbsp;DelveInsight<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=craniopharyngioma-pipeline-clinical-trials-and-companies-novartis-blaze-bioscience-bristol-myers-squibb-insys-therapeutics-zafgen\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=craniopharyngioma-pipeline-clinical-trials-and-companies-novartis-blaze-bioscience-bristol-myers-squibb-insys-therapeutics-zafgen\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s Craniopharyngioma Pipeline Insight, 2023&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Craniopharyngioma market. A detailed picture of the Craniopharyngioma pipeline landscape is provided, which includes &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/craniopharyngioma-pipeline-clinical-trials-and-companies-novartis-blaze-bioscience-bristol-myers-squibb-insys-therapeutics-zafgen_658644.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,403,404],"tags":[],"class_list":["post-658644","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/658644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=658644"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/658644\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=658644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=658644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=658644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}